For the Inventor, By the Inventor

Enter assignee name

Poxel Sa

USPTO Granted Patents = 12

CIPO Patents = 6

EPO Patents = 4

Forward Citations = 2

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Vincent Jacques (6 out of 29 patents)

Sheila DeWitt (5 out of 21 patents)

Sébastien Bolze (4 out of 11 patents)

4. Leonardus Van Der Ploeg (4 out of 4 patents)

5. Anthony W Czarnik (3 out of 32 patents)

6. Laure Françoise Valérie Navarre (2 out of 2 patents)

7. Bill Symonds (2 out of 2 patents)

8. Steve Piscitelli (2 out of 2 patents)

9. Karen Segal (2 out of 2 patents)

10. Ruby Holder (2 out of 2 patents)

11. Sophie Bozec (2 out of 2 patents)

12. Pascale Fouqueray (2 out of 2 patents)

13. Christophe Arbet-Engels (2 out of 2 patents)

14. Julie Dubourg (2 out of 2 patents)

15. Paul Strumph (2 out of 4 patents)

12 patents: Sort by Forward Citations

1. 12036226 - Methods of treating subjects having diabetes with chronic kidney disease (2024-07-16),

2. 11918569 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2024-03-05),

3. 11918567 - Deuterium-enriched pioglitazone (2024-03-05),

4. 11767317 - Methods of synthesizing enantiopure deuterium-enriched pioglitazone (2023-09-26),

5. 11617754 - Methods of treating heart failure with preserved ejection fraction (2023-04-04),

6. 11319313 - Crystalline forms of deuterium-enriched pioglitazone (2022-05-03),

7. 11266652 - Methods of treating subjects having diabetes with chronic kidney disease (2022-03-08),

8. 11141411 - Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone (2021-10-12),

9. 11123336 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2021-09-21),

10. 10940143 - Deuterium-enriched pioglitazone (2021-03-09),

11. 10576071 - Deuterium-enriched pioglitazone (2020-03-03),

12. 10265305 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2019-04-23),

Poxel SA is a biopharmaceutical company focused on developing innovative treatments for metabolic diseases. Their lead product candidate, Imeglimin, is being developed for the treatment of type 2 diabetes. Poxel is also working on a pipeline of programs targeting other metabolic disorders, such as non-alcoholic steatohepatitis (NASH) and rare diseases. With a strong commitment to research and development, Poxel aims to improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

12 Patents

#26 in Lyons

#1,453 in France

#46,665 in the World

Poxel Sa

Forward Citations = 2

26 inventors:

Vincent Jacques (6 out of 29 patents)

Sheila DeWitt (5 out of 21 patents)

Sébastien Bolze (4 out of 11 patents)

4. Leonardus Van Der Ploeg (4 out of 4 patents)

5. Anthony W Czarnik (3 out of 32 patents)

Please report any incorrect information to support@idiyas.com

Loading…